Remus Pharmaceuticals IPO Details
- Open Date 17-May-23
- Close Date 19-May-23
- Lot Size 100
- IPO Size ₹ 47.69 Cr
- IPO Price Range ₹ 1150 to ₹ 1229
- Min Investment ₹ 115000
- Listing Exchange NSE SME
- Basis of Allotment 24-May-23
- Refunds 25-May-23
- Credit to Demat Account 26-May-23
- Listing Date 29-May-23
Remus Pharmaceuticals IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 17 May'23 | 0.00x | 2.85x | 2.85x | 1.43x |
| 18 May'23 | 1.48x | 12.25x | 10.93x | 6.41x |
| 19 May'23 | 10.75x | 229.29x | 49.58x | 57.12x |
Remus Pharmaceuticals IPO Synopsis
Remus Pharmaceuticals Limited is engaged in the marketing and distributing finished formulations of pharmaceutical drugs. IPO worth ₹47.69 Crores opens on 17th May and closes on 19th May.
The issue consists of a fresh issue of equity shares aggregating to ₹47.69 crores. The price band for the issue is fixed at Rs.1150 to Rs.1229 per share. The lot size is set for 100 shares per lot. The shares will be allotted on the 24th of May and the issue will be listed on the 29th of May on the stock exchanges.
The book running lead managers to the offer is Beeline Capital Advisors Pvt Ltd
Objective of Remus Pharmaceuticals
The Net Proceeds from the Fresh Issue will be utilized towards the following objects:
1. To Meet Working Capital Requirements
2. Funding investments for acquisitions and general corporate purposes
3. To meet Public Issue Expenses
About Remus Pharmaceuticals
Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
- APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
- Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.
The portfolio consists of 429 products, as of January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries.
As on January 31, 2023, a total of 134; products are under the process of registration in 16 countries.
Check out Web-stories on Remus Pharmaceuticals IPO
Check Remus Pharmaceuticals IPO GMP
Check out Web-stories on Remus Pharmaceuticals IPO GMP
Remus Pharmaceuticals Financial Status
Profit and Loss
Balance Sheet
| Particulars (in Rs. Crores) | FY22 | FY21 | FY20 |
|---|---|---|---|
| Revenue | 2,471.71 | 1,841.81 | 1,191.90 |
| EBITDA | 479.07 | 156.82 | 124.24 |
| PAT | 338.57 | 102.58 | 81.16 |
| Particulars (in Rs. Crores) | FY22 | FY21 | FY20 |
|---|---|---|---|
| Total Assets | 1,590.93 | 1,104.96 | 530.36 |
| Share Capital | 187.66 | 180 | 180 |
| Total Borrowings | 19.17 | 27.89 | 35.93 |
| Particulars (in Rs. Crores) | FY22 | FY21 | FY20 |
|---|---|---|---|
| Net cash generated from / (used in) operating activities | 503.78 | 283.79 | 130.26 |
| Net cash from / (used in) investing activities | (454.54) | (309.02) | (55.92) |
| Net cash flow from / (used in) financing activities | (17.44) | (11.54) | 6.42 |
| Net increase (decrease) in cash and cash equivalents | 114.86 | 83.05 | 119.81 |
Remus Pharmaceuticals IPO Key Points
-
Strengths
1. Experienced Promoters and Management Team.
2. Wide range of Products.
3. Strategic Location of Contract Manufacturing Facilities.
4. Diversified business operations and revenue base.
5. Scalable Business Model. -
Risks
1. There are outstanding legal proceedings involving the Company, its Directors, its Promoters, and Group Companies.
2. The Company is dependent on a few number of customers for sales. Loss of any of these large customers may affect our revenues and profitability
3. The Company is dependent on a few suppliers for the purchase of products. The loss of any of these large suppliers may affect business operations.
4. Registered office, corporate office, and warehouse, from where the company operates are not owned by the company.
How to apply for IPO?
-
Login to your 5paisa account and select the issue in the
current IPO section -
Enter the number of lots and price at which you wish to
apply for -
Enter your UPI ID and click on submit. With this, your
bid will be placed with the exchange -
You will receive a mandate notification to block funds in
your UPI app -
Approve the mandate request on your UPI and funds
will be blocked
Open account in 5 minutes
Be a part of the 5paisa community now with 10 million mobile app users
Remus Pharmaceuticals IPO FAQs
What is the minimum lot size for the Remus Pharmaceuticals IPO?
The minimum lot size of Remus Pharmaceuticals IPO is Rs. 1150 to Rs. 1229.
What is the price band of the Remus Pharmaceuticals IPO?
The price band of Remus Pharmaceuticals IPO is Rs. 1150 to Rs. 1229
When does the Remus Pharmaceuticals IPO opens and closes?
The Remus Pharmaceuticals IPO opens on May 17, 2023 and closes on May 19, 2023.
What is the size of the Remus Pharmaceuticals IPO?
The Remus Pharmaceuticals IPO comprises of a fresh issue of equity shares aggregating to ₹47.69 crores.
What is the allotment date of Remus Pharmaceuticals IPO?
The allotment date of Remus Pharmaceuticals IPO is 24th May 2023.
What is the Remus Pharmaceuticals IPO listing date?
The Remus Pharmaceuticals IPO listing date is 29th May 2023.
Who are the book runners for Remus Pharmaceuticals IPO?
The book runners for Remus Pharmaceuticals IPO is Beeline Capital Advisors Pvt Ltd.
What is the objective of Remus Pharmaceuticals IPO?
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
1. To Meet Working Capital Requirements
2. Funding investments for acquisitions and general corporate purposes
3. To meet Public Issue Expenses
How to apply for the Remus Pharmaceuticals IPO?
To apply for the Remus Pharmaceuticals IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and price at which you wish to apply for
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
● You will receive a mandate notification to block funds in your UPI app
Contact Details of Remus Pharmaceuticals IPO
Contact Information
Remus Pharmaceuticals Limited
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad - 380054
Phone: +079- 2999 9857
Email: cs@remuspharma.com
Website: http://www.remuspharma.com/
Remus Pharmaceuticals IPO Register
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Remus Pharmaceuticals IPO Lead Manager
Beeline Capital Advisors Pvt Ltd